Angiodynamics receives 510(k) clearance for alphavac f1885 system in treatment of pe

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the united states food and drug administration (fda) has cleared the alphavac f1885 system for the treatment of pulmonary embolism (pe), enhancing its utility in critical medical scenarios such as pe. pe affect.
ANGO Ratings Summary
ANGO Quant Ranking